… in migraine. We assessed its efficacy and tolerability in patients with episodic migraine in
whom previous treatment with two-to-four migraine preventives had been unsuccessful. …

… ) included patients with episodic migraine (EM) who received placebo or erenumab at 7 mg,
… Patients who entered the open-label treatment phase (OLTP) initially received erenumab at …

… We report analyses of the ATP of the STRIVE study, which aimed to assess the efficacy,
tolerability, and safety of erenumab through 52 weeks and to assess the effect of switching doses…

… of erenumab in participants with episodic or chronic migraine across the age groups < 40
years, 40–49 years, 50–59 years, and ≥ 60 years was completed. The safety of erenumab …

… This study provides data on the safety and tolerability profiles … as preventive treatments for
episodic migraine. In addition to … , migraine AE did appear to be more frequent with erenumab …

… safety and clinical superiority of erenumab compared to placebo in chronic migraine (CM).
The aim of this analysis is to evaluate the effectiveness and tolerability of erenumab in a real-…

… In the 12-week, real-life, EARLY (ErenumAb in Real Life in Italy… tolerability of erenumab in
373 patients with migraine affected by high-frequency episodic migraine (HFEM: ≥8 migraine …

… and tolerability in high-frequency episodic migraine (HFEM: ≥8 monthly migraine days, …
of treatment with erenumab in the ongoing 12-month EARLY (Erenumab in Real Life in Italy…

… and excellent tolerability will be … chronic and episodic migraine trials with fremanezumab
[57], and meta-analysis of the phase II and III chronic and episodic migraine trails of erenumab […

… All patients had discontinued their use of at least two preventive medications for migraine
due to lack of efficacy or tolerability, as documented in medical records. The median number of …